Fistula News and Research

RSS

A Fistula is an abnormal opening or passage between two organs or between an organ and the surface of the body. Fistulas may be caused by injury, infection, or inflammation, or may be created during surgery.

Long-term data demonstrates clinical benefits of Exelixis XL184 for medullary thyroid cancer

Exelixis, Inc. today reported long-term results in a cohort of 37 medullary thyroid cancer (MTC) patients who participated in the phase 1 study of XL184. Dr. Razelle Kurzrock from the MD Anderson Cancer Center in Houston, TX will present the data in a Clinical Science Symposium (Abstract #5502) on Monday, June 7 at 10:15 AM at the 2010 Annual Meeting of the American Society of Clinical Oncology in Chicago.

21 May 2010

New case report addresses diagnostic significance of CT and MRI for DCF

Duodenocaval fistula is an uncommon but lethal clinical entity. The high mortality has been attributed to the difficulty of diagnosis before attempts at definitive therapy.

13 May 2010

MBPs offer no clinical benefit to patients undergoing PD: Research team

Mechanical bowel preparations are commonly administered preoperatively to patients who undergo a pancreaticoduodenectomy (Whipple procedure) to treat benign and malignant tumors of the pancreas, common bile duct or duodenum. MBPs are employed as a preventative measure in gastrointestinal surgery but their effectiveness in reducing perioperative infectious complications remains unclear.

7 May 2010

Results of study comparing REMICADE to azathioprine for Crohn's disease published

Findings published today in The New England Journal of Medicine from a first-of-its-kind comparator trial evaluating the anti-tumor necrosis factor (TNF)-alpha biologic treatment REMICADE (infliximab) in the treatment of moderately to severely active Crohn's disease in patients who were naive to immunomodulator and biologic therapy, showed that a significantly greater proportion of patients receiving REMICADE achieved steroid-free remission and mucosal healing compared with patients receiving azathioprine.

16 Apr 2010

Data from Phase 2 clinical trials of Hematide/peginesatide presented at NKF Annual Meeting

Affymax, Inc. and Takeda Global Research & Development Center, Inc., U.S., today announced data from several post hoc analyses of Phase 2 clinical trials that evaluated Hematide/peginesatide in dialysis patients with anemia in chronic kidney disease. The data provide hypotheses for further investigation of this agent in anemia management in this patient population.

16 Apr 2010

Hemosphere completes $9.3M venture capital financing

Hemosphere, Inc., a private medical device company, has completed a late round of venture capital financing totaling $9.3 million. The company has developed the HeRO® Vascular Access Device, which provides access for hemodialysis - the process of filtering waste products from blood when kidneys are in renal failure - similar to a conventional graft.

1 Apr 2010

Genentech announces topline results from Phase III trial of Avastin

Genentech, Inc., a wholly owned member of the Roche Group, announced today the topline results of a Phase III trial led by the U.S. Cancer and Leukemia Group B (CALGB) and sponsored by the National Cancer Institute investigating the use of Avastin® (bevacizumab) in combination with docetaxel chemotherapy and prednisone in men with late stage prostate cancer (hormone-refractory / HRPC).

12 Mar 2010

Opinions: Haiti corruption; Financial sector tax, G8 promises; Investing in women

A Washington Post editorial reflects on Haitian President Rene Preval's response to U.S. policy makers' queries "about the perils of corruption and what measures the Haitian government might devise to minimize misuse and theft of the billions of dollars in recovery assistance flowing into the country and the billions more expected" during his visit this week to Washington D.C. "Surprisingly, he seems utterly unprepared to discuss the matter," the editorial notes.

12 Mar 2010

HDI announces results of Rapid Maternal Mortality and Obstetric Fistula Prevention Project

In honor of the 100th anniversary of International Women's Day, Health & Development International (HDI) announced the results of its Rapid Maternal Mortality and Obstetric Fistula Prevention Project today, in advance of its second hosted global meeting on this topic to be held at The Carter Center in Atlanta on March 9 and 10.

8 Mar 2010

Data evaluating safety, efficacy of STELARA and REMICADE in patients with plaque psoriasis to be presented

Data evaluating the efficacy and safety of STELARA™ (ustekinumab) and REMICADE® (infliximab) in patients with plaque psoriasis who had an inadequate response to Enbrel® (etanercept) will be presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) in Miami, Fla., from March 5-9, 2010.

5 Mar 2010

Advanced ovarian cancer: Avastin-chemotherapy combination followed by Avastin alone improves PFS

Genentech, Inc., a wholly owned member of the Roche Group, today announced that a Phase III study showed the combination of Avastin® (bevacizumab) and chemotherapy followed by maintenance use of Avastin alone increased the time women with previously untreated advanced ovarian cancer lived without the disease worsening (progression-free survival or PFS), compared to chemotherapy alone. A preliminary assessment of safety noted adverse events previously observed in pivotal trials of Avastin.

25 Feb 2010

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

Genentech, Inc., a wholly owned member of the Roche Group, today announced that a Phase III study (AVAGAST) did not meet its primary endpoint of showing Avastin® (bevacizumab) plus Xeloda® (capecitabine) or 5-FU and cisplatin chemotherapy extended the lives of people with inoperable or advanced stomach (gastric) cancer, compared to chemotherapy alone.

23 Feb 2010

Study shows benefits of stent grafts over balloon angioplasty for patients who undergo dialysis

A randomized multicenter study of 190 patients at 13 medical centers shows-- for the first time-- the "superior" benefit of stent grafts over balloon angioplasty for maintaining function of dialysis access grafts in kidney failure patients who undergo dialysis. Until now, no other therapy has proven more effective than angioplasty.

12 Feb 2010

Pervasis Therapeutics reaches agreement with FDA on pivotal Phase 3 clinical trial for Vascugel

Pervasis Therapeutics, Inc. today announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of a pivotal Phase 3 clinical trial for Vascugel®, an investigational new drug for the prevention of hemodialysis access graft failure.

2 Feb 2010

Obama administration supports Cairo conference goals, Clinton says

Secretary of State Hillary Rodham Clinton on Friday "reiterated the Obama administration's support" for universal access to family planning, improving maternal health care and other goals outlined at the 1995 International Conference on Population and Development Action Plan held in Cairo, Egypt, All Headline News reports.

12 Jan 2010

AUA updates clinical practice guideline on female stress urinary incontinence

A complete evaluation, including an assessment of post-void residual volume, is key when evaluating a female patient for surgery to treat stress urinary incontinence (SUI), according to a new clinical practice guideline released today by the American Urological Association (AUA).

8 Jan 2010

VOA News examines obstetric fistula in Africa

VOA News examines obstetric fistula in Africa and looks at health officials' efforts to prevent and treat the condition.

24 Dec 2009

Genentech announces Phase III study of Avastin in women treated with chemotherapy for advanced breast cancer

Genentech, Inc., a wholly owned member of the Roche Group, today announced results from a Phase III study (RIBBON 2) of Avastin® (bevacizumab) in women who had previously been treated with initial (first-line) chemotherapy for advanced HER2-negative breast cancer and needed additional (second-line) treatment.

14 Dec 2009

More investment in family planning and pregnancy-related care will reduce maternal and newborn deaths

Maternal deaths in developing countries could be slashed by 70% and newborn deaths cut nearly in half if the world doubled investment in family planning and pregnancy-related care, shows a new report by the Guttmacher Institute and UNFPA, the United Nations Population Fund. Currently, more than half a million maternal deaths and 3.5 million newborn deaths, many of them easily preventable, occur each year in developing countries.

4 Dec 2009

Proteon Therapeutics commences PRT-201 Phase 1/2 clinical study in hemodialysis patients

Proteon Therapeutics, Inc., has initiated a Phase 1/2 human clinical study of its lead product, PRT-201, in end-stage renal disease (ESRD) patients undergoing surgery for arteriovenous graft (AVG) creation. The AVG study represents Proteon's second human clinical study in hemodialysis patients, previously announcing the initiation of a Phase 1/2 study of PRT-201 in ESRD patients undergoing surgery for arteriovenous fistula (AVF) creation earlier this year.

23 Nov 2009